LIMITATIONS
• Using claims data to define PEx is not validated.
• Due to its small sample size, this study was not powered to show a difference in the primary endpoint. • Pharmacy claims are not a true measure of patient adherence to a medication in the outpatient setting, and data was not available to identify inpatient medication administration. • Clinical parameters, such as pulmonary function data, were not available.
DISCUSSION

OBJECTIVE
To compare CF PEx rates pre-and post-initiation of LUM/IVA in one state's Medicaid program.
METHODS
This retrospective, observational cohort study utilized pharmacy and medical claims and prior authorization data.
Enrollment
• Members of one state's fee-for-service (FFS) and managed Medicaid plan with ≥ 1 pharmacy claim for LUM/IVA between July 2, 2015 (Food and Drug Administration-approval date) and September 30, 2016.
• Inclusion criteria:
-Age ≥ 6 years -Diagnosis of CF and homozygous for the F508del mutation • Exclusion criteria:
-Medicaid was secondary payer -Any break in Medicaid coverage during the study period
Outcomes
• The date of the first pharmacy claim for LUM/IVA was defined as the index date. Data was collected six months pre-and post-index date.
• Demographic data collected included gender, age, baseline CF medications, and complications of CF.
• The primary outcome was annualized rate of PEx per member pre-and post-index date.
-PEx was defined as any combination of claims for the following events: CF PEx or respiratory infection ICD-10 code related to (1) an emergency room (ER) visit or (2) inpatient hospitalization or (3) pharmacy claim for an oral or intravenous antibiotic (excluding macrolides). -A gap of ≥ 7 days between events was considered a new PEx event.
• Secondary outcomes included the annualized days of PEx per member and a breakdown of the number and type of events that corresponded to each PEx pre-and post-LUM/IVA initiation.
• A subgroup analysis was performed for adherent members (calculated as proportion of days covered [PDC] ≥ 0.8).
Statistical Analysis
• Descriptive statistics were used to report demographics and outcomes.
• Chi-square and paired t-test were used to test for significance among categorical and continuous variables, respectively.
RESULTS
CONCLUSIONS
• This claims analysis did not find a statistically significant difference in the rate of PEx after initiation of LUM/IVA in a real-world cohort of CF patients in a Medicaid program, although numerical improvement was observed in a subset of adherent members.
• Further investigation is warranted to better understand LUM/IVA medication use patterns in this population and impact on disease state.
• Our findings support that interventions to improve adherence to CF treatments may represent a strategy for a payer to improve health outcomes for their members.
Non-adherence to LUM/IVA was commonly observed in our study population, which for some members may be indicative of treatment discontinuation. This finding is consistent with other real-world outcomes studies demonstrating that approximately 17% to 40% of patients discontinue treatment due to adverse events. 3, 4 There was no statistically significant difference in the annualized rate of PEx and days of PEx per member in the pre-LUM/IVA period compared to the post-LUM/IVA period.
• Among adherent members, the annualized rate of PEx decreased in the post-LUM/ IVA period compared to the pre-LUM/IVA period. Annualized days of PEx per member marginally increased. However, these changes were not considered to be significant. 
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